Compare NNAVW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNAVW | GALT |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 199.2M |
| IPO Year | N/A | 2008 |
| Metric | NNAVW | GALT |
|---|---|---|
| Price | $9.10 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 162.4K | ★ 348.5K |
| Earning Date | 03-12-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,963,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.44 | N/A |
| 52 Week Low | $3.90 | $1.27 |
| 52 Week High | $13.41 | $7.13 |
| Indicator | NNAVW | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 54.57 |
| Support Level | $4.98 | $2.09 |
| Resistance Level | $12.99 | $2.60 |
| Average True Range (ATR) | 1.28 | 0.23 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 17.67 | 44.71 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.